- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05552651
Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
September 21, 2022 updated by: Tao Jiang
A Single-arm, Exploratory Clinical Study of Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
The objective is to investigate the efficacy and safety of envafolimab combined with chemotherapy for preoperative neoadjuvant therapy in patients with resectable esophageal squamous cell carcinoma
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is a single-arm, exploratory phase II clinical study.
In the study, all patients with esophageal squamous cell carcinoma who meet the inclusion criteria will receive 3 cycles (21 days of 1 cycle) of neoadjuvant envolizumab combined with chemotherapy Treatment, radical surgery 4-6 weeks after completion of the last neoadjuvant therapy.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tao Jiang
- Phone Number: 13991230762
- Email: 2585408668@qq.com
Study Contact Backup
- Name: shi cao li
- Phone Number: 029-84717761
- Email: tangduec@126.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The subjects voluntarily joined the study, signed the informed consent form, and had good compliance;
- 18-75 years;
- ECOG 0-1;
- life expectancy of at least 3 months;
- For patients diagnosed with thoracic esophageal squamous cell carcinoma by histopathological examination of the primary tumor, the stage of esophageal cancer was clearly diagnosed as cT1b-cT2 N+ or cT3-cT4a anyN stage by CT or MRI or color Doppler ultrasound or PET-CT or ultrasonography before surgery , and evaluated by the investigator as suitable for patients treated with this study protocol.
- Not received any anti-tumor therapy in the past, including but not limited to surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy, etc. However, exploratory thoracotomy, mediastinoscopy, excisional biopsy or similar surgical procedures for definite diagnosis, staging and surgical treatment of esophageal cancer can be accepted.
- Satisfactory main organ function,laboratory test must meet the following criteria: hemoglobin (HGB) ≥90g/L, neutrophil count(ANC) ≥1.5×109/L, platelet count(PLT) ≥80×109/L, Serum creatinine(CR)≤1.5 upper normal limitation (UNL),total bilirubin (TBil) ≤1.5 upper normal limitation (UNL), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 UNL (For patients with liver metastasis, the AST/ALT must be ≤5.0 UNL), Activated partial thromboplastin time (APTT), international normalized ratio (INR), prothrombin time (PT) ≤ 1.5×ULN; left ventricular ejection fraction (LVEF) ≥ 50%; thyroid stimulating hormone (TSH) within the normal range Within: if the baseline TSH exceeds the normal range, subjects with total T3 (or FT3) and FT4 within the normal range can also be enrolled;
- The doctor's clinical judgment has sufficient organ function;
- Subjects of childbearing potential must use an appropriate method of contraception during the study period and within 120 days after the end of the study, have a negative serum pregnancy test within 7 days prior to study enrollment, and must be non-lactating subjects ;
Exclusion Criteria:
- Suffered from other malignant tumors within 5 years before the start of treatment in this study;
- Patients with tumor invading the cervical esophagus or high upper thoracic segment requiring a laryngectomy;
- Patients with a high risk of bleeding or perforation due to the obvious invasion of the tumor into the adjacent organs (aorta or trachea) of the esophageal lesion, or patients who have already formed a fistula;
- Subjects with any severe and/or uncontrolled disease;
- Poor blood pressure control (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90mmHg);
- Subjects with any severe and/or uncontrolled disease ;
- Have clinical symptoms or diseases of the heart that are not well controlled;
- Patients with past and current objective evidence of history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severely impaired lung function;
- Acute or chronic active hepatitis B (hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive patients need to be tested for hepatitis B virus (HBV) DNA, such as HBV DNA copy number ≤2×103 copies/ml or ≤200 IU/ml or below the lower limit of detection, can be enrolled. HBsAg (+) subjects should receive anti-HBV therapy throughout the study drug treatment period to avoid viral activation. For anti-HBV Subjects with HBc(+), HBsAg(-), anti-HBs(-) and HBV viral load(-) do not need to receive preventive anti-HBV treatment, but need to be closely monitored for virus reactivation;
- A history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation;
- Poor control of diabetes (fasting blood glucose [FBG]> 10mmol/L);
- Clinically active diverticulitis, abdominal abscess, gastrointestinal obstruction;
- Those who have received major surgical treatment, incision biopsy or obvious traumatic injury within 28 days before the start of study treatment; or have long-term unhealed wounds or fractures;
- Serious arterial/venous thrombotic events, such as cerebrovascular accident (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep venous thrombosis and pulmonary embolism, occurred within 6 months before the start of study treatment;
- Those who have a history of psychotropic substance abuse and cannot quit or have mental disorders;
- Patients who have received tumor treatment in the past;
- Subjects with uncontrolled pleural effusion, pericardial effusion or ascites (judgment by the investigator) who still need repeated drainage;
- Subjects with known central nervous system metastases and/or cancerous meningitis;
- History of vaccination with live attenuated vaccine within 14 days before the start of study treatment or planned vaccination with live attenuated vaccine during the study period;
- Active autoimmune disease requiring systemic treatment (such as the use of disease-modifying drugs, corticosteroids or immunosuppressants) within 2 years before the start of study treatment, alternative therapy (such as thyroxine, insulin, or adrenal or pituitary use) Physiological corticosteroids with insufficiency, etc.) are excluded;
- Diagnosed with immunodeficiency or receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy. (dose>10mg/day prednisone or other equivalent therapeutic hormones), and continued use within 2 weeks of the first administration;
- Those with a history of active tuberculosis;
- Within 4 weeks before the start of the study, are participating in or have participated in other clinical investigators;
- Those who have been treated with other PD-1/PD-L1 inhibitors in the past cannot be enrolled; the subjects are known to be allergic to macromolecular protein preparations, or known to be allergic to the applied drug components;
- Those who are known to be allergic to the active ingredients or excipients of the study drugs such as envolimab, nab-paclitaxel, and nedaplatin;
- According to the judgment of the investigator, there are concomitant diseases that seriously endanger the safety of the subjects or affect the completion of the study, or subjects who are considered unsuitable for enrollment for other reasons.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Envafolimab plus chemotherapy
|
300mg,sc,d1,Q3W;
130mg/m2,iv,D1,D8,Q3W
AUC=5, iv,D1,Q3W
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of pCR
Time Frame: From Baseline to primary completion date, about 6 months
|
Rate of pathological complete remission
|
From Baseline to primary completion date, about 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of MPR
Time Frame: From Baseline to primary completion date, about 6 months
|
Rate of major pathological remission
|
From Baseline to primary completion date, about 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of SAE
Time Frame: From Baseline to primary completion date, about 18 months
|
Rate of severity Adverse Event
|
From Baseline to primary completion date, about 18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
September 20, 2022
Primary Completion (ANTICIPATED)
December 20, 2023
Study Completion (ANTICIPATED)
December 20, 2023
Study Registration Dates
First Submitted
September 14, 2022
First Submitted That Met QC Criteria
September 21, 2022
First Posted (ACTUAL)
September 23, 2022
Study Record Updates
Last Update Posted (ACTUAL)
September 23, 2022
Last Update Submitted That Met QC Criteria
September 21, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Neoplasms, Squamous Cell
- Esophageal Neoplasms
- Carcinoma
- Carcinoma, Squamous Cell
- Esophageal Squamous Cell Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Carboplatin
- Paclitaxel
- Albumin-Bound Paclitaxel
Other Study ID Numbers
- 202208-20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Squamous Cell Carcinoma
-
Cancer Institute and Hospital, Chinese Academy...Akeso Pharmaceuticals, Inc.Not yet recruitingMetastatic Esophageal Squamous Cell Carcinoma | Unresectable Esophageal Squamous Cell Carcinoma | Locally Advanced Esophageal Squamous Cell Carcinoma
-
National Cancer Institute (NCI)TerminatedEsophageal Cancer | Esophageal Neoplasms | Esophageal Adenocarcinoma | Squamous Cell Carcinoma | Esophageal Squamous Cell CancerUnited States
-
Peking UniversityUnknownAdvanced Esophageal Squamous CarcinomaChina
-
Fujian Medical University Union HospitalNot yet recruitingEsophageal Squamous Cell Carcinoma Thoracic Stage II | Esophageal Squamous Cell Carcinoma Thoracic Stage III | Esophageal Squamous Cell Carcinoma Thoracic Stage IVChina
-
The First Affiliated Hospital of Henan University...Luoyang Central Hospital; Nanyang Central Hospital; Sanmenxia Central Hospital; Military 150 Hospital and other collaboratorsActive, not recruitingStage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell CarcinomaChina
-
The First Affiliated Hospital of Henan University...UnknownStage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell CarcinomaChina
-
Jiangsu Cancer Institute & HospitalRecruitingLocally Advanced Esophageal CarcinomaChina
-
Shanghai Zhongshan HospitalZhejiang Cancer Hospital; Sun Yat-sen University; Cancer Institute and Hospital... and other collaboratorsRecruitingEsophageal Squamous Cell Carcinoma Stage II | Esophageal Squamous Cell Carcinoma Stage IIIChina
-
The First Affiliated Hospital of Henan University...UnknownStage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell CarcinomaChina
-
The First Affiliated Hospital of Henan University...UnknownStage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell Carcinoma | Stage I Esophageal Adenocarcinoma | Stage II Esophageal Adenocarcinoma | Stage III Esophageal Adenocarcinoma | Stage I Esophageal Squamous Cell CarcinomaChina
Clinical Trials on Envafolimab
-
Anhui Provincial Cancer HospitalNot yet recruitingNon-small Cell Lung Cancer Stage IIIChina
-
Fudan UniversityNot yet recruitingLocally Advanced Rectal Carcinoma | MSI-High
-
The First Affiliated Hospital of Xiamen UniversityActive, not recruitingNon-small Cell Lung Cancer Stage IVChina
-
Northern Jiangsu Province People's HospitalRecruiting
-
3D Medicines (Sichuan) Co., Ltd.Recruiting
-
Peking Union Medical College HospitalNot yet recruitingEfficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruiting
-
Hairong LiuNot yet recruiting
-
Jiangsu Cancer Institute & HospitalNot yet recruiting
-
Chipscreen Biosciences, Ltd.Active, not recruitingNon Small Cell Lung CancerChina